Corcept Therapeutics Incorporated Stock Investor Sentiment

CORT Stock  USD 54.85  0.15  0.27%   
Slightly above 58% of Corcept Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Corcept Therapeutics Incorporated stock suggests that many investors are alarmed at this time. Corcept Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Corcept Therapeutics' earnings reports, geopolitical events, and overall market trends.

Comfort Level 42

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Corcept Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Corcept Therapeutics Incorporated.

Corcept Historical Sentiment

Although Corcept Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Corcept, such as negative comments on social media and news outlets, may cause fear in the market and push Corcept Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Corcept.
  

Corcept Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Corcept Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Corcept Therapeutics Historical Investor Sentiment

Investor biases related to Corcept Therapeutics' public news can be used to forecast risks associated with an investment in Corcept. The trend in average sentiment can be used to explain how an investor holding Corcept can time the market purely based on public headlines and social activities around Corcept Therapeutics Incorporated. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Corcept Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Corcept Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Corcept Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Corcept Therapeutics.

Corcept Therapeutics Maximum Pain Price Across June 20th 2025 Option Contracts

Corcept Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Corcept Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Corcept Therapeutics' options.
over a week ago at businesswire.com         
FDA Files Corcepts New Drug Application for Relacorilant as Treatment for Patients With Hypercortiso...
businesswire News
over a week ago at thelincolnianonline.com         
Corcept Therapeutics Downgraded by StockNews.com to Hold
news
over a week ago at thelincolnianonline.com         
HC Wainwright Reiterates Buy Rating for Corcept Therapeutics
news
over a week ago at finance.yahoo.com         
Why Corcept Therapeutics is a Top Growth Stock for the Long-Term
Yahoo News
over a week ago at simplywall.st         
Corcept Therapeutics five-year total shareholder returns outpace the underlying earnings growth
Simply Wall St News at Macroaxis
over a week ago at finance.yahoo.com         
Is Corcept Therapeutics Outperforming Other Medical Stocks This Year?
Yahoo News
over a week ago at zacks.com         
Why Corcept Therapeutics is a Top Growth Stock for the Long-Term
zacks News
over a week ago at zacks.com         
Acquisition by Gary Robb of 140000 shares of Corcept Therapeutics at 60.58 subject to Rule 16b-3
zacks News
over a week ago at finance.yahoo.com         
3 Reasons Why Growth Investors Shouldnt Overlook Corcept
Yahoo News
over a week ago at gurufocus.com         
Decoding Corcept Therapeutics Inc A Strategic SWOT Insight
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Corcept Therapeutics Incorporateds Intrinsic Value Is Potentially 48 percent Above Its Share Price
Yahoo News
over a week ago at zacks.com         
3 Reasons Why Growth Investors Shouldnt Overlook Corcept
zacks News
over a week ago at finance.yahoo.com         
Why Corcept Therapeutics is a Top Momentum Stock for the Long-Term
Yahoo News
over a week ago at benzinga.com         
Corcept Therapeuticss Options A Look at What the Big Money is Thinking
benzinga news
over a week ago at zacks.com         
Why Corcept Therapeutics is a Top Momentum Stock for the Long-Term
zacks News
Far too much social signal, news, headlines, and media speculation about Corcept Therapeutics that are available to investors today. That information is available publicly through Corcept media outlets and privately through word of mouth or via Corcept internal channels. However, regardless of the origin, that massive amount of Corcept data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Corcept Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Corcept Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Corcept Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Corcept Therapeutics alpha.

Corcept Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 7800 shares by Wilson James N of Corcept Therapeutics subject to Rule 16b-3
12/27/2024
2
Disposition of 11000 shares by Gary Robb of Corcept Therapeutics at 3.29 subject to Rule 16b-3
01/02/2025
3
Disposition of 3037 shares by Gary Robb of Corcept Therapeutics at 3.29 subject to Rule 16b-3
01/03/2025
4
Acquisition by Sean Maduck of 20000 shares of Corcept Therapeutics at 3.88 subject to Rule 16b-3
01/06/2025
5
Disposition of 2200 shares by Swisher Daniel N Jr of Corcept Therapeutics at 50.54 subject to Rule 16b-3
01/10/2025
6
Disposition of 250000 shares by Wilson James N of Corcept Therapeutics at 3.29 subject to Rule 16b-3
01/22/2025
7
Is Corcept a Solid Growth Stock 3 Reasons to Think Yes
01/24/2025
8
Disposition of 1571 shares by Joseph Lyon of Corcept Therapeutics at 11.35 subject to Rule 16b-3
02/03/2025
9
Disposition of 2200 shares by Swisher Daniel N Jr of Corcept Therapeutics at 68.08 subject to Rule 16b-3
02/10/2025
10
Disposition of 150000 shares by Hazel Hunt of Corcept Therapeutics at 3.29 subject to Rule 16b-3
02/11/2025
11
Corcept Therapeutics Inc Q4 Earnings EPS of 0.26 Misses Estimate, Revenue at 181. ...
02/26/2025
12
Corcept Therapeuticss Options A Look at What the Big Money is Thinking
02/27/2025
13
3 Reasons Why Growth Investors Shouldnt Overlook Corcept
02/28/2025
14
FDA Files Corcepts New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
03/03/2025
15
Corcepts NDA for its hypercortisolism treatment gets FDA nod
03/04/2025
16
We Think Corcept Therapeutics Solid Earnings Are Understated
03/05/2025
17
Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock
03/07/2025
18
NVO Stock Down 9 percent as CagriSema Misses Target in Second Obesity Study
03/11/2025

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.